| Literature DB >> 35407582 |
Inha Woo1, Jeongjin Park1, Hyungyu Seok1, Tae-gon Kim2, Jun Sung Moon3, Seung Min Chung3, Chul Hyun Park4.
Abstract
Forefoot osteomyelitis can be an extremely challenging problem in orthopedic surgery. Unlike conventional methods, such as amputations, antibiotic impregnated cement space (ACS) was recently introduced and perceived as a substitute for amputation. The purpose of this study was to compare clinical features between diabetic and non-diabetic groups and to evaluate the efficacy of ACS in the treatment of forefoot osteomyelitis, by identifying the clinical characteristics of ACS. We inserted ACS into the forefoot osteomyelitis patients and regularly checked up on them, then analyzed the clinical features of the patients and failure reasons, if ACS had to be removed. Average survival rate of ACS was 60% (21 out of 35 cases) and main failure reason was recurrence of infection. There was no significant clinical difference between diabetic and non-diabetic groups. We concluded that ACS could be a possible way of avoiding amputation if infection is under control. ACS seems to be an innovative method with promising results for foot osteomyelitis, but widely accepted indications need to be agreed upon.Entities:
Keywords: antibiotics impregnated cement spacer; diabetic foot; forefoot osteomyelitis; single center study
Year: 2022 PMID: 35407582 PMCID: PMC8999527 DOI: 10.3390/jcm11071976
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Patient selection flow chart. (* One patient belonging to the diabetic group occurred on the left and right for different periods, respectively, and was considered as each case).
Demographic features and final status of ACS between diabetic and non-diabetic group of the patients.
| Demographic Data ( | |||
|---|---|---|---|
| Variable | Patients with DM ( | Patients without DM ( | |
| Age (yr) | 0.83 | ||
| Median | 64 | 60 | |
| IQR | 60.0–75.3 | 51–67 | |
| Sex | 1 | ||
| Male | 21 | 6 | |
| Female | 6 | 2 | |
| Follow-up (months) | 0.28 | ||
| Median | 16.7 | 34 | |
| IQR | 15.6–39.8 | 17–48.6 | |
| BMI (kg/m2) | 0.529 | ||
| Median | 22.7 | 22.7 | |
| IQR | 21.4–24 | 21.3–27.3 | |
| Comorbidity | |||
| Hypertension | 14 | 2 | 0.244 |
| Renal disease which requires hemodialysis | 6 | 0 | 0.299 |
| Cardiac diseases | 7 | 0 | 0.16 |
| Location | 0.313 | ||
| Phalanx (joint not involved) | 15 | 7 | |
| joint involvement | 10 | 1 | |
| Metatarsals (joint not involved) | 2 | 0 | |
| Maintenance of ACS | 0.858 | ||
| Remained | 15 | 6 | |
| Removed | 12 | 2 |
Abbreviatoin: IQR (interquartile range), BMI, body mass index. DM, diabetes mellitus.
Microbiological results from cultures proceeded at operation rooms.
| The Microbiological Findings from Cultures at Operation Room | |
|---|---|
| Organisms | Number |
|
| 2 |
|
| 8 |
|
| 4 |
|
| 4 |
|
| 1 |
|
| 4 |
|
| 2 |
|
| 3 |
|
| 1 |
|
| 1 |
|
| 2 |
| no growth | 3 |
| multiple organisms | 0 |
| Total | 35 |
Abbreviation: MRSA, Methicillin resistant staphylococcus aureus. Multiple organism group is not counted into individual group.
Figure 2A 62-year-old male patient with diabetes who had had first phalanges infection and ACS insertion and received additional surgery due to uncontrolled infection. (A) The X-ray presentation of ACS insertion initially. (B) The radiograph after first ray amputation performed. (C) Pus filled with dead space after ACS was removed intraoperatively.
This table shows comparison between ACS retention group and ACS removed group.
| Comparing between ACS Retension Group and ACS Removed Group | |||
|---|---|---|---|
| Variable | ACS Retension Group (N = 21) | ACS Removed Group (N = 14) | |
| Age (yr) | 60.00 (52.5–68) | 58.00 (53.50–73.25) | 0.96 |
| mean Ankle brachial index (ABI) | 1.16 (1.08–1.22) | 1.096 (1.13–1.17) | 0.503 |
| mean Toe brachial index (TBI) | 0.77 (0.48–0.89) | 1.01 (0.93) | 0.03 |
| Numbers of previous surgeries before ACS insertion | 0 (0–2.5) | 0 (0.5–2) | 0.594 |
Median (IQR). Patients evaluated with 3D angio CT or unable to be evaluated were excluded.
This table shows clinical features of ACS failure group.
| Features of Why and Where ACS Were Failed, Time to Failure (%) | |
|---|---|
| Variables | |
| Retained ACS cases | 21 (60%) |
| ACS removed cases | 14 (40%) |
| Additional amputation needed | 1 (7.1%) |
| Reasons why ACS were removed | |
| infection not controlled | 8 (57.1%) |
| wound problem (such as skin penetraion, not healed op scar) | 5 (35.7%) |
| difficulty in walking | 1 (7.1%) |
| Location of ACS being failed (total number of each group) | |
| phalanx | 6 (out of 22, 27%) |
| MPJ (joint involved) | 5 (out of 11, 45%) |
| metatarsals | 2 (out of 2, 100%) |
| Other * | 1 (out of 1, 100%) |
| Time to failure in ACS removed groups (days) | |
| mean | 348 |
| Range | 2 to 2332 |
Abbreviations: MPJ Metatarsophalangeal joint. *: This patient had osteomyelitis on 1st metatarsal head and 5th distal phalanx.
Antibiotics list of systemic antibiotic therapy.
| Category of Antibiotics Prescribed to the Failure Group | |
|---|---|
| Variable | Number |
| Cephalosporins (first to third generation) | 5 |
| Piperacillin/Tazobactam | 1 |
| Floroquinolones | 4 |
| Vancomycin | 1 |
| Tigecycline | 1 |
| Carbapenem | 2 |
| Total | 14 |